Active, not recruitingPHASE1, PHASE2NCT03899792

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eli Lilly and Company
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Intervention: Selpercatinib(drug)
Enrollment: 36 enrolled
Eligibility: 21 years · All sexes
Timeline: 2019 – 2029

Study locations (26)

Childrens Hospital of Los Angeles, Los Angeles, California, United States
The Children's Hospital for Cancer and Blood Disorders, Aurora, Colorado, United States
Nemours Children's Health, Orlando, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Minnesota Hospital, Minneapolis, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Texas Childrens Hospital, Houston, Texas, United States
Seattle Children's Hospital Research Foundation, Seattle, Washington, United States
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Royal Children's Hospital, Melbourne, Victoria, Australia
The Hospital for Sick Children, Toronto, Ontario, Canada
+11 more locations on ClinicalTrials.gov

Collaborators

Loxo Oncology, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03899792 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma →

← Back to all trials